Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

Cortex COR gedumpt

52 Posts
Pagina: «« 1 2 3 »» | Laatste | Omlaag ↓
  2. [verwijderd] 22 februari 2007 20:13

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Ksm00225 schreef:

    voorlopig geen nieuws te vinden...
    Vond dit op Yahoo, van de Roth conferentie:

    CX717 update:

    -histo events ARE post mortem
    -the histo event is now clearly documented
    -submission to FDA will occur in mid-March
    -electron microscope shows tissue as CLEAN
    -final tox study will be finished by months end
    -"I think we will get the dose limit lifted"
    -"data is coming in firmly"
    -over time structural changes seen after chemicals (ie: formaldehyde) are added Cortex

    Online comment 2/22/07

    Cortex was surprisingly definitive in their presentation at Roth Capital yesterday: the cellular 'signal' which has hamstrung the CX717 program since last April is a post-mortem artifact--it only occurs in tissue which is being prepared with a formalin-based fixative. If the same target tissue is instead frozen, the cellular signal is not seen, even when examined via electron microscope. Even the FDA will find it near-impossible to object to a resumption of full-dosage ADHD trials when the signal of concern only occurs after death. CEO Roger Stoll said quite bluntly--"I think we'll be able to get the dose limitation lifted by the FDA." No hedging with anything like 'of course, the final decision will be up to the FDA...' Cortex will submit the full package to the FDA in mid-March, and we expect a 'go' decision from the FDA in May. It has been a long wait, but it appears that CX717, which has now been more thoroughly vetted than any other Phase II drug, is in fact safe, and will go back into ADHD, where the initial findings were so positive. It was also timely in that this occurred on the day that the FDA announced that all current ADHD drugs would have to include inserts detailing their safety risks. CX717 appears to have none of their side effect baggage. This will add to the program's lustre as a partnerhip candidate, in addition to the high-impact group, where a partnership is expected midyear. Cortex is now in a position to resume the upward trajectory that was so abruptly interrupted last April--which for those who lost track during the interim, had the share price over 5. We expect it back in--and perhaps above--that range during 2007.

    Sentiment : Strong Buy

    Weet niet wat ervan waar is, maar heb toch een plukkie opgepakt!
  5. forum rang 4 Nel 22 februari 2007 21:55

    • Nel

      Lid sinds: 04 apr 2004

      Laatste bezoek: 22 mei 2024

    • Aanbevelingen

      Ontvangen: 1406

      Gegeven: 219

    •    Aantal posts: 27.755

    quote:

    papaa schreef:

    ga met je mee,zie idd kansen ,news is onderweg.

    succes
    ben blij met de aankoop
  8. [verwijderd] 22 februari 2007 22:15

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    The Wishbone schreef:

    Plukje gekocht op 1.56

    Positief is ze hebben geld binnen gehaald op 27 januarie

    Partner is akzonobel

    We zullen het zien.

    Op Yahoo zijn ze in ieder geval erg positief!
  13. [verwijderd] 22 februari 2007 23:38

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    De toegelaten dosis van cx717 werd door de fda vorig jaar tot een max beperkt. Gevolg daling tot $1. Cox heeft nu gezegd dat hij zeker is dat deze beperking door de fda wordt opgeheven en dat koers weer naar de $5 zal stijgen.

    Cortex

    Online comment 2/22/07

    Cortex was surprisingly definitive in their presentation at Roth Capital yesterday: the cellular 'signal' which has hamstrung the CX717 program since last April is a post-mortem artifact--it only occurs in tissue which is being prepared with a formalin-based fixative. If the same target tissue is instead frozen, the cellular signal is not seen, even when examined via electron microscope. Even the FDA will find it near-impossible to object to a resumption of full-dosage ADHD trials when the signal of concern only occurs after death. CEO Roger Stoll said quite bluntly--"I think we'll be able to get the dose limitation lifted by the FDA." No hedging with anything like 'of course, the final decision will be up to the FDA...' Cortex will submit the full package to the FDA in mid-March, and we expect a 'go' decision from the FDA in May. It has been a long wait, but it appears that CX717, which has now been more thoroughly vetted than any other Phase II drug, is in fact safe, and will go back into ADHD, where the initial findings were so positive. It was also timely in that this occurred on the day that the FDA announced that all current ADHD drugs would have to include inserts detailing their safety risks. CX717 appears to have none of their side effect baggage. This will add to the program's lustre as a partnerhip candidate, in addition to the high-impact group, where a partnership is expected midyear. Cortex is now in a position to resume the upward trajectory that was so abruptly interrupted last April--which for those who lost track during the interim, had the share price over 5. We expect it back in--and perhaps above--that range during 2007.

    www.neuroinvestment.com/CORXcom.html

  14. [verwijderd] 23 februari 2007 05:00

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    After Hours
    Last: $ 1.75 After Hours
    High: $ 1.75
    After Hours
    Volume: 10,200 After Hours
    Low: $ 1.62

    After Hours
    Time (ET) After Hours
    Price After Hours
    Share Volume
    18:01 $ 1.69 100
    18:01 $ 1.69 100
    18:01 $ 1.69 300
    18:01 $ 1.75 1,400
    17:48 $ 1.64 100
    17:48 $ 1.67 500
    17:21 $ 1.64 100
    17:21 $ 1.64 400
    16:39 $ 1.62 900
    16:39 $ 1.62 3,600
    16:07 $ 1.64 100
    16:07 $ 1.64 300
    16:06 $ 1.64 100
    16:02 $ 1.62 2,200
  15. [verwijderd] 23 februari 2007 16:56

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Laatste koers Verschil

    1.87 USD 0.23 (14.02 %)
    Volume Tijdstip
    1976200 2007-02-23 16:53:52
    Slotkoers Openingskoers
    1.64 1.87
    Laagste v/d dag Hoogste v/d dag
    1.75 1.98


  18. [verwijderd] 23 februari 2007 19:00

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    "New information indicates that CX717 may be nontoxic," wrote analyst Elemer Piros, upgrading the stock to "Market Outperform" from "Market Perform" with a $4.50 price target.

    quote:

    skippy44 schreef:

    Ja het is hier windstil.Ook nog geen reactie op Cnlg.

    Laatste koers Verschil

    1.85 USD 0.21 (12.8 %)
  19. [verwijderd] 23 februari 2007 19:52

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    The Wishbone schreef:

    Iemand er nog in of hebben jullie al winst gepakt?

    Koers 1,89
    Ik zit er nog Wish! Gisteren fors ingestapt en heerlijk van de rit aan het genieten! Ik blijf voorlopig ook heerlijk zitten!

    succes!
52 Posts
Pagina: «« 1 2 3 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.854
AB InBev 2 5.311
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 47.274
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 9.055
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 167
ADMA Biologics 1 32
Adomos 1 126
AdUX 2 457
Adyen 13 16.717
Aedifica 2 844
Aegon 3.257 320.409
AFC Ajax 537 7.029
Affimed NV 2 5.802
ageas 5.843 109.785
Agfa-Gevaert 13 1.900
Ahold 3.536 74.034
Air France - KLM 1.024 34.396
AIRBUS 1 2
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.779
Alfen 13 17.526
Allfunds Group 3 1.239
Almunda Professionals (vh Novisource) 651 4.247
Alpha Pro Tech 1 17
Alphabet Inc. 1 342
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.779
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.822 240.564
AMG 965 126.748
AMS 3 73
Amsterdam Commodities 303 6.527
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 384
Antonov 22.632 153.605
Aperam 91 14.205
Apollo Alternative Assets 1 17
Apple 5 322
Arcadis 251 8.630
Arcelor Mittal 2.024 318.786
Archos 1 1
Arcona Property Fund 1 272
arGEN-X 15 9.193
Aroundtown SA 1 189
Arrowhead Research 5 9.316
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.789
ASML 1.762 77.871
ASR Nederland 18 4.165
ATAI Life Sciences 1 7
Atenor Group 1 347
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.818
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.683

Macro & Bedrijfsagenda

  1. 29 mei

    1. Consumentenvertrouwen juni (Dld)
    2. Consumentenvertrouwen mei (Fra)
    3. ASR jaarvergadering
    4. Hypotheekaanvragen - wekelijks (VS)
    5. Inflatie mei, vlpg (Dld)
    6. OCI jaarvergadering
    7. Federal Reserve - Beige Book (VS)
    8. HP Q2-cijfers (VS)
    9. Salesforce Q1-cijfers (VS)

  2. 30 mei

    1. Azerion Q1-cijfers
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda